Abstract
ObjectivesTo assess the long-term safety and efficacy of the Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in the ongoing long-term extension (LTE) of SELECT-COMPARE, a randomised controlled phase...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have